טוען...

IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors

PURPOSE: Somatic mutations in IDH1/2 occur in ~20% of patients with myeloid neoplasms, including acute myeloid leukemia (AML). IDH1/2(MUT) enzymes produce D-2-hydroxyglutarate (D2HG), which associates with increases in DNA damage and improved responses to chemo/radiotherapy and PARP inhibitors in so...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
הוצא לאור ב:	Clin Cancer Res
Main Authors:	Molenaar, Remco J., Radivoyevitch, Tomas, Nagata, Yasunobu, Khurshed, Mohammed, Przychodzen, Bartolomiej, Makishima, Hideki, Xu, Mingjiang, Bleeker, Fonnet E., Wilmink, Johanna W., Carraway, Hetty E., Mukherjee, Sudipto, Sekeres, Mikkael A., van Noorden, Cornelis J.F., Maciejewski, Jaroslaw P.
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	2018
נושאים:	Article
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5884732/ https://ncbi.nlm.nih.gov/pubmed/29339439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2796
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors

פריטים דומים